TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta, Biologics, Antibody, Claudin 18.2

TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Careers Contact
背景

TST004

MASP2
Target:
MASP2
Indication:
IgA/TMA Nephropathy
Project Status:
Phase I

TST004 is a humanized mAb targeting mannan-binding lectin serine protease 2 (MASP2) and designed to prevent the inflammation and tissue damage mediated by lectin pathway complement activation. TST004 is currently at IND-enabling stage with GLP toxicology studies and CMC studies ongoing.


t004.jpg

Nature Reviews Nephrology (2017) 13:311–318 


TOP